Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses

被引:16
作者
Pia Holgado, Maria [1 ]
Falivene, Juliana [1 ]
Maeto, Cynthia [1 ]
Amigo, Micaela [1 ]
Fernanda Pascutti, Maria [1 ,4 ]
Belen Vecchione, Maria [1 ,2 ]
Bruttomesso, Andrea [2 ]
Calamante, Gabriela [3 ]
Paula del Medico-Zajac, Maria [3 ]
Magdalena Gherardi, Maria [1 ]
机构
[1] Univ Buenos Aires, Fac Med, CONICET, Inst Invest Biomed Retrovirus & SIDA INBIRS, RA-1121 Buenos Aires, DF, Argentina
[2] Univ Buenos Aires, Unidad Microanal & Metodos Fis Aplicados Quim Org, Dept Quim Organ, Fac Ciencias Exactas & Nat, RA-1428 Buenos Aires, DF, Argentina
[3] CICVyA INTA Castelar, Inst Biotecnol, RA-1686 Buenos Aires, DF, Argentina
[4] Sanquin Res, Dept Hematopoiesis, NL-1066 CX Amsterdam, Netherlands
来源
VIRUSES-BASEL | 2016年 / 8卷 / 05期
关键词
MVA; vaccine; T-cell response; MEMORY STEM-CELLS; TRANSCRIPTION FACTORS; CLINICAL DEVELOPMENT; I INTERFERON; STRAIN MVA; ANKARA; PROTEINS; HOST; DIFFERENTIATION; INFECTION;
D O I
10.3390/v8050139
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
MVA is an attenuated vector that still retains immunomodulatory genes. We have previously reported its optimization after deleting the C12L gene, coding for the IL-18 binding-protein. Here, we analyzed the immunogenicity of MVA vectors harboring the simultaneous deletion of A44L, related to steroid synthesis and A46R, a TLR-signaling inhibitor (MVAA44L-A46R); or also including a deletion of C12L (MVAC12L/A44L-A46R). The absence of biological activities of the deleted genes in the MVA vectors was demonstrated. Adaptive T-cell responses against VACV epitopes, evaluated in spleen and draining lymph-nodes of C57Bl/6 mice at acute/memory phases, were of higher magnitude in those animals that received deleted MVAs compared to MVAwt. MVAC12L/A44L-A46R generated cellular specific memory responses of higher quality characterized by bifunctionality (CD107(a/b)(+)/IFN-(+)) and proliferation capacity. Deletion of selected genes from MVA generated innate immune responses with higher levels of determining cytokines related to T-cell response generation, such as IL-12, IFN-, as well as IL-1 and IFN-. This study describes for the first time that simultaneous deletion of the A44L, A46R and C12L genes from MVA improved its immunogenicity by enhancing the host adaptive and innate immune responses, suggesting that this approach comprises an appropriate strategy to increase the MVA vaccine potential.
引用
收藏
页数:21
相关论文
共 70 条
  • [11] Sensitive and viable identification of antigen-specific CD8+T cells by a flow cytometric assay for degranulation
    Betts, MR
    Brenchley, JM
    Price, DA
    De Rosa, SC
    Douek, DC
    Roederer, M
    Koup, RA
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 281 (1-2) : 65 - 78
  • [12] Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins:: implications for use as a human vaccine
    Blanchard, TJ
    Alcamí, A
    Andrea, P
    Smith, GL
    [J]. JOURNAL OF GENERAL VIROLOGY, 1998, 79 : 1159 - 1167
  • [13] GLUCOCORTICOID THERAPY FOR IMMUNE-MEDIATED DISEASES - BASIC AND CLINICAL CORRELATES
    BOUMPAS, DT
    CHROUSOS, GP
    WILDER, RL
    CUPPS, TR
    BALOW, JE
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (12) : 1198 - 1208
  • [14] A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling
    Bowie, A
    Kiss-Toth, E
    Symons, JA
    Smith, GL
    Dower, SK
    O'Neill, LAJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (18) : 10162 - 10167
  • [15] Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line
    Carroll, MW
    Moss, B
    [J]. VIROLOGY, 1997, 238 (02) : 198 - 211
  • [16] Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy
    Clark, RH
    Kenyon, JC
    Bartlett, NW
    Tscharke, DC
    Smith, GL
    [J]. JOURNAL OF GENERAL VIROLOGY, 2006, 87 : 29 - 38
  • [17] Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
    Cottingham, Matthew G.
    Andersen, Rikke F.
    Spencer, Alexandra J.
    Saurya, Saroj
    Furze, Julie
    Hill, Adrian V. S.
    Gilbert, Sarah C.
    [J]. PLOS ONE, 2008, 3 (02):
  • [18] Modified Vaccinia Virus Ankara Triggers Type I IFN Production in Murine Conventional Dendritic Cells via a cGAS/STING-Mediated Cytosolic DNA-Sensing Pathway
    Dai, Peihong
    Wang, Weiyi
    Cao, Hua
    Avogadri, Francesca
    Dai, Lianpan
    Drexler, Ingo
    Joyce, Johanna A.
    Li, Xiao-Dong
    Chen, Zhijian
    Merghoub, Taha
    Shuman, Stewart
    Deng, Liang
    [J]. PLOS PATHOGENS, 2014, 10 (04)
  • [19] Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine
    Dangoor, Adam
    Lorigan, Paul
    Keilholz, Ulrich
    Schadendorf, Dirk
    Harris, Adrian
    Ottensmeier, Christian
    Smyth, John
    Hoffmann, Klaus
    Anderson, Richard
    Cripps, Martin
    Schneider, Joerg
    Hawkins, Robert
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (06) : 863 - 873
  • [20] Interleukin-1-and Type I Interferon-Dependent Enhanced Immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef Vaccine Vector with Dual Deletions of Type I and Type II Interferon-Binding Proteins
    Delaloye, Julie
    Filali-Mouhim, Abdelali
    Cameron, Mark J.
    Haddad, Elias K.
    Harari, Alexandre
    Goulet, Jean-Pierre
    Gomez, Carmen E.
    Perdiguero, Beatriz
    Esteban, Mariano
    Pantaleo, Giuseppe
    Roger, Thierry
    Sekaly, Rafick-Pierre
    Calandra, Thierry
    [J]. JOURNAL OF VIROLOGY, 2015, 89 (07) : 3819 - 3832